We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A Virginia-based biotech company has announced dosing of ...

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening rare diseases by harnessing the power of the immune ...

Phase I Evaluation of Prolonged-Infusion Gemcitabine With Mitoxantrone for Relapsed or Refractory Acute Leukemia PURPOSE: This prospective clinical study was begun in 1994 to validate the independent ...

In a recent study published in Respiratory Medicine, researchers reported that silent hypoxia was not unique to coronavirus disease 2019 (COVID-19). Silent hypoxemia syndrome, well-tolerated hypoxemia ...

The combination of a vascular endothelial growth factor (VEGF) –neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in ...

Results of a VHIO led study show that up to 90% of chronically hypoxic patients have an EPAS1 alteration in their tumor, a gene critical for adapting to lack of oxygen in populations living at ...

While many serious cases of COVID-19 are marked by respiratory distress and dangerously low blood oxygen levels—a condition referred to as hypoxia—the occurrence of "silent or happy hypoxia" affecting ...